What Is a Chondral Defect and How Is It Treated?

A chondral defect is a patch of damaged or missing cartilage on the smooth surface that lines the ends of bones inside a joint. Most commonly found in the knee, these defects range from shallow softening of the cartilage surface to full-thickness holes that expose the bone underneath. Because articular cartilage has no blood supply of its own, it has very limited ability to repair itself, which makes even a small area of damage a potentially lasting problem.

Why Cartilage Struggles to Heal

The cartilage coating your joint surfaces is fundamentally different from most other tissues in your body. Skin, muscle, and bone all receive a steady supply of blood, and blood carries the stem cells, growth factors, and nutrients that drive healing. Articular cartilage is avascular, meaning it lacks its own blood vessels entirely, so it depends on the fluid inside the joint for nutrition.¹ That arrangement keeps the surface slick and nearly frictionless, but it also means the body’s usual repair toolkit barely reaches a damaged area. The result is that a chondral defect, left alone, tends to stay the same size or slowly worsen rather than close itself the way a skin wound would.

Chondral Versus Osteochondral Defects

If you encounter the term “osteochondral defect,” the key difference is depth. A purely chondral defect stays within the cartilage layer. An osteochondral defect punches through the cartilage and into the bone beneath it. That distinction matters for treatment planning because bone, unlike cartilage, does bleed, so an osteochondral lesion at least has some natural healing response from the exposed marrow. One study comparing the two types in the ankle joint found that chondral-type lesions were more frequently associated with subchondral cysts and soft tissue impingement than their osteochondral counterparts.² In practical terms, some surgical techniques work for both types while others are better suited to one or the other, so your surgeon will want to know exactly how deep the damage goes.

What Chondral Defects Feel Like

Symptoms depend on the size and location of the defect. Small lesions can be completely silent, showing up as incidental findings during imaging or surgery for another problem. Larger defects tend to cause activity-related joint pain, swelling after exercise, and a sensation of stiffness. Some people notice catching or locking, as though something is in the way when they bend the joint, though those mechanical symptoms can also come from meniscal tears or loose fragments of cartilage floating in the joint.³

Compared with older adults who have widespread osteoarthritis, people with isolated chondral defects tend to be younger, more physically active, and less willing to scale back their activity level.⁴ That profile creates a tricky gap: the people most affected by these defects are the ones who put the most stress on their joints. Pain during or after sports, especially cutting and pivoting movements, is a common reason young athletes and recreational runners end up getting a diagnosis.

How Chondral Defects Are Diagnosed and Graded

MRI is the frontline imaging tool. It can show the location of a defect, estimate its depth, and pick up changes in the bone underneath. A meta-analysis across eight studies found that MRI had an overall sensitivity of about 75% and specificity of about 94% for detecting chondral lesions.⁵ In plain terms, MRI is quite good at ruling in a defect when it sees one, but it misses roughly a quarter of real lesions. If clinical suspicion is high and the MRI looks normal, surgeons may still proceed to a diagnostic arthroscopy, which remains the gold standard for directly viewing the cartilage surface.

Newer three-dimensional MRI sequences have improved accuracy, with 3.0-Tesla scanners significantly outperforming older 1.5-Tesla machines.⁶ If your imaging was done at a facility with an older magnet, a repeat scan on a higher-field machine may reveal details the first one missed.

Once a defect is confirmed, it is graded using the ICRS (International Cartilage Repair Society) classification, which runs from Grade 1 (superficial softening) through Grade 4 (full-thickness loss exposing bone). MRI-based scoring systems like AMADEUS have been developed to estimate ICRS severity without surgery, showing moderate correlation with what surgeons find when they look inside the joint.⁷ That grading feeds directly into treatment decisions: a Grade 1 or 2 defect may be managed conservatively, while a Grade 3 or 4 often points toward surgery.

Conservative Treatment

Not every chondral defect needs an operation. A structured rehabilitation program built around load management, neuromuscular retraining, and progressive strengthening forms the backbone of nonsurgical care.⁸ The goal is to reduce stress on the damaged area, strengthen the muscles that stabilize the joint, and manage symptoms so you can stay active without making the defect worse. Weight loss (if relevant), activity modification, anti-inflammatory medications, and sometimes bracing or taping round out the approach.

Conservative management tends to work best for smaller or lower-grade defects and for patients whose activity demands are moderate. In younger, highly active patients, cartilage defects often cause enough pain and functional limitation that surgery eventually enters the conversation, even though the defect may not necessarily progress to full-blown osteoarthritis in the short term.⁹ For osteochondral lesions in the ankle specifically, pooled data across studies showed a clinical success rate of roughly 45% with nonsurgical treatment, and about one in ten patients showed signs of the defect worsening on follow-up imaging.¹⁰ Those numbers suggest that conservative care buys meaningful relief for many, but a substantial group will eventually need something more.

Surgical Options

When conservative care falls short, several surgical strategies exist. The choice depends on factors including the size and location of the defect, your alignment, body weight, and how much you expect to demand from the joint.¹¹ Interestingly, patient age alone has not been shown to reliably predict outcomes across techniques. Here is how the main procedures work.

Microfracture

Microfracture is the simplest and most widely available surgical option. A surgeon uses a small pick or awl to poke tiny holes through the base of the defect into the underlying bone marrow. Blood and stem cells seep up through the holes, form a clot, and eventually mature into a repair tissue. The catch is that this repair tissue is mainly fibrocartilage, not the hyaline cartilage that originally lined the joint. Fibrocartilage is tougher and less smooth, with weaker biomechanical properties, and it tends to break down over time.¹² Because of that durability concern, microfracture works best for smaller defects and is often considered a first-line procedure, with more involved techniques held in reserve if the repair fails.

Cell-Based Repair With MACI

Matrix-induced autologous chondrocyte implantation, or MACI, is a two-stage procedure. First, a small biopsy of healthy cartilage is harvested from the patient’s knee and sent to a lab, where the cartilage cells are grown on a collagen scaffold. A few weeks later, the scaffold loaded with the patient’s own cells is implanted into the defect. The key advantage over microfracture is the quality of the repair tissue: biopsies taken after MACI show hyaline-like cartilage forming as early as six months after surgery.¹³ Hyaline-like cartilage more closely resembles the original surface than the fibrocartilage produced by microfracture.¹⁴

Long-term follow-up is encouraging. A systematic review looking at outcomes beyond ten years found significant and lasting improvements in patient-reported outcomes, with follow-up MRI showing satisfactory defect fill in most patients. The all-cause reoperation rate was about 9%, and roughly 7% of patients eventually progressed to knee replacement over 10 to 17 years.¹⁵ That is a meaningful success rate for a procedure dealing with tissue the body ordinarily cannot repair.

Osteochondral Grafting

For defects where both cartilage and bone are damaged, or where other approaches have failed, surgeons can transplant plugs of cartilage-and-bone taken either from a non-weight-bearing part of the patient’s own knee (autograft) or from a donor (allograft). A meta-analysis comparing the two approaches found no significant difference in graft survival, with both autograft and allograft showing roughly 88% survival at about five years.¹⁶ Autografts avoid any risk of immune rejection but are limited by the amount of donor tissue available from a single knee. Allografts can cover larger defects but depend on tissue bank availability and carry a small risk of disease transmission.

Platelet-Rich Plasma and Other Biologics

Platelet-rich plasma, or PRP, has drawn considerable interest as an add-on treatment. It is made by concentrating platelets from a sample of your own blood, which delivers a burst of growth factors to the treatment site. PRP can be injected into the joint on its own or used alongside a surgical repair. A review of both lab and clinical studies found that most research reports a positive effect on cartilage injury, with improvements in joint function, though results have not been uniform across all studies.¹⁷ When paired with microfracture, PRP-treated patients in one study recovered function and experienced pain relief faster, though the advantage narrowed by twelve months and did not reach statistical significance at that point.¹⁸

PRP is relatively low-risk since it comes from your own blood, but insurance coverage varies widely, and the lack of standardized preparation protocols means that one clinic’s PRP may contain a very different concentration of growth factors than another’s. It is best viewed as a potentially helpful supplement rather than a standalone fix for a structural cartilage defect.

Getting Back to Activity After Surgery

Rehabilitation after cartilage repair is slow compared with many other knee procedures. The repaired tissue needs time to mature and bond with surrounding cartilage before it can handle the loads of running, cutting, and jumping. Timelines vary by procedure, but returning to pivoting sports after cartilage repair surgery generally takes the better part of a year or longer.¹⁹

A meta-analysis of professional athletes found an overall return-to-sport rate of about 84%, though many returned at a level below their pre-injury performance.²⁰ Rates vary by procedure. A systematic review of athletes’ knees found return-to-sport rates were highest after osteochondral autograft transplantation (about 89%), followed closely by osteochondral allograft and autologous chondrocyte implantation, with microfracture at about 75%.²¹ Scoping reviews looking specifically at pivoting sports showed wider ranges, with microfracture return rates as low as 44% and osteochondral autograft as high as 100% depending on the study.²² The takeaway is that most people do return to activity, but setting realistic expectations about the timeline and the level of play is an important part of the process.

Does an Untreated Defect Lead to Arthritis?

This is one of the most common worries, and the honest answer is: probably yes over the long run, though the timeline is uncertain. A review of the literature found that patients with untreated focal chondral defects are more likely to experience worsening cartilage damage over time, but the studies included did not show radiographically evident osteoarthritis developing within two years of follow-up.²³ That means the progression is real but slow, giving you a window to explore treatment before the joint deteriorates significantly. Still, the lack of a fast timeline should not breed complacency. A defect that causes symptoms and goes untreated for years is not benign; the damaged edges continue to fray, and the surrounding cartilage absorbs extra load.

The Cost Question

Procedure costs are a real factor in decision-making, especially when the simpler option produces good short-term results. In a German claims-data analysis, MACI treatment carried about 1.6 times the five-year total cost of microfracture. The bulk of the extra expense was front-loaded in the year of surgery itself. Interestingly, by years four and five, the cost picture reversed: microfracture patients were racking up higher annual healthcare costs than MACI patients, likely reflecting additional treatments for fibrocartilage breakdown.²⁴ A separate review of level 1 and 2 studies still concluded that microfracture is more cost-effective overall at five years, mainly because the initial surgery is so much cheaper.²⁵ What neither analysis fully captures is what happens beyond five years. If microfracture’s fibrocartilage repair deteriorates and the patient eventually needs a second procedure or joint replacement, the long-run economics could favor the pricier cell-based technique. Cost-effectiveness analyses using newer ACI formulations have begun to suggest exactly that.²⁶

3D Bioprinting and the Future of Cartilage Repair

The next frontier is growing replacement cartilage in the lab using 3D bioprinting. The idea is to deposit living cells, scaffold materials, and growth factors layer by layer into a structure that mimics the natural zones of articular cartilage. Early studies have demonstrated the ability to replicate the mechanical properties of real cartilage and build in the layered architecture that gives healthy joints their strength and slipperiness.²⁷ Recent work on gradient scaffolds has further refined the approach, aiming to replicate the transition from cartilage into bone at the base of the defect.²⁸

Much of the preclinical testing happens in animal models. Large animals with thick articular cartilage, particularly horses, are considered the closest approximation to human joints in terms of cartilage and bone thickness, and they allow researchers to test repairs under athletic exercise conditions that resemble the stresses a human knee endures.²⁹ Polymer-based tissue-engineered grafts have already been tested in equine full-thickness cartilage defects, and the results feed directly into the design of scaffolds intended for human use.³⁰ These technologies remain experimental, with no commercially available bioprinted cartilage implant on the market yet. But the pace of development is fast enough that today’s patients with smaller defects treated by microfracture may see bioprinted options available by the time they need a revision, which is a realistic and encouraging prospect.